Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,655 JPY | +1.67% | +1.95% | +18.28% |
03-20 | Kissei Pharmaceutical Completes 6 Billion Yen Buyback Program | MT |
03-19 | Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023. | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The group's high margin levels account for strong profits.
- The company appears to be poorly valued given its net asset value.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.28% | 1.06B | - | ||
+5.48% | 71.19B | A | ||
+12.55% | 9.3B | A- | ||
-13.75% | 5.01B | A- | ||
+42.38% | 4.47B | - | ||
+4.51% | 3.96B | B- | ||
+21.10% | 2.44B | B | ||
-19.05% | 2.41B | C- | ||
-28.72% | 2.23B | - | ||
+11.13% | 2.02B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4547 Stock
- Ratings Kissei Pharmaceutical Co., Ltd.